INPHARMATIS: Inpharmatis Team COVID-19 Update

March 30, 2020

Inpharmatis Team COVID-19 Update

We are taking all necessary measures to reduce the spread of the COVID-19 virus. The safety of our clients, partners and employees is our priority. Therefore, we have canceled all personal meetings and planned training courses. Due to the COVID-19 expansion geographically, also most GMP inspections have been suspended, traveling limited and a lot of companies begin teleworking.

Our team is continuing to work remotely, and available in normal working hours to support you during this difficult time as best as possible.

We value and respect our client’s business and are committed to delivering results by knowledgeable focus, meeting deadlines and professional project management despite the global COVID-19 situation.

Our team of highly experienced experts is highly committed to supporting you during this difficult time as best as possible by continuing to provide full pharmaceutical product life-cycle management over the whole of EU & CIS in pharmacovigilance, regulatory affairs, medical writing, market access services and a range of specific software to the pharmaceutical industry.

To maintain our client’s business continuity, we are delighted also to propose comprehensive and detailed GMP audit reports of active pharmaceutical ingredients (API) manufacturers performed by Inpharmatis.

Schedule with us virtual meetings and find out how can we help you. Please email your request to info@inpharmatis.com or call us +371 6721 0500.

Our CEO Dr. P.Dombure is reminding and repeatedly advising all employees, clients, and partners to practice a social distancing and take all proper hygiene steps thus reducing the risk of infection or spreading the infection to others.

Stay strong and healthy!

Kind regards,

Inpharmatis team